The UnitedHealth story

What drives the business

• UnitedHealth combines insurance premiums with care delivery, technology and pharmacy services, with the Centers for Medicare & Medicaid Services accounting for 44% of consolidated revenue through premium payments in 2025.
• UnitedHealthcare covers employers, individuals, Medicare beneficiaries and Medicaid members, while Optum Health delivers care through arrangements that include accepting responsibility for medical costs in exchange for a monthly premium.
• Optum Rx managed $188 billion in pharmaceutical spending in 2025 and is shifting toward clearly defined per-member fees rather than incentives tied to prescription volume.
• Optum Insight provides technology and administrative services under multiyear arrangements, with approximately $31.1 billion in backlog at December 2025, including $12.9 billion from affiliated agreements and anticipated renewals within the overall backlog.
• Optum supported more than 120 million consumers in the quarter to June 2026, generating $65.7 billion in revenue and $4.0 billion in operating earnings, with 160 basis points of margin expansion from a year earlier.

What the price assumes

TenQ does not measure the growth implied by UnitedHealth's price through a reverse DCF because an insurer's free cash flow does not measure what it earns.

TenQ's earnings valuation check places the earnings multiple at 24.37 against its historical comparison of 17.68, while its growth check finds no positive three-year earnings growth behind the price.

The earnings yield of 4.1% also falls short of the 5.2% Treasury benchmark used by TenQ, although the cash yield of 7.0% exceeds its historical comparison of 6.4%.

What could change the story

• The medical care ratio improved to 86.7% in the quarter to June 2026 from 89.4% a year earlier, but it benefited from $860 million of favorable reserve development, making the source of further improvement important.
• The operating cost ratio increased to 12.7% from 12.3% a year earlier as UnitedHealth invested in technology, operations and community support, adding costs alongside the medical margin recovery.
• Over the last twelve months, profit growth was -33.7% and revenue growth was 6.5%, below the three-year annual pace of 11.4%, so the June 2026 earnings recovery contrasts with a weaker longer record.
• Dependence on government programs exposes UnitedHealth to payment changes, risk adjustment audits and the Department of Justice's legal actions concerning its Medicare participation.
• Total debt of $73.3 billion compares with $31.5 billion in cash and short-term investments, while TenQ's debt trend check fails because debt relative to equity has risen over five years.

What to watch next

• The next releases will test the full year 2026 adjusted earnings outlook of $19.50 to $20.00 per share and medical care ratio outlook of 88.1% plus or minus 25 basis points, particularly the contribution from reserve development.
• Membership trends and pharmacy volumes will show whether contraction continues after Optum Rx adjusted prescriptions fell to 387 million in the quarter to June 2026 from 414 million a year earlier.
• Cash flow deserves comparison with the full year 2026 outlook of approximately $24,000 million from operations, because the $11.1 billion generated in the quarter to June 2026 partly reflected the timing of a substantial government payment.
• Progress on Optum Rx's fee-based model and its commitment to pass through 100% of manufacturer drug rebate discounts to clients by January 2028 will show how its pharmacy business is changing.

Sources

• UnitedHealth's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The UNH stock report, for every figure and check